GMDA - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell's Conference Call for the Fourth Quarter and Full Year 2021 Financial Results. My name is Howard and I'll be your operator for today's call. Please be advised that this call is being recorded at Gamida Cell's request.

Now, I would like to introduce your host for today's conference, Heather DiVecchia, Gamida Cell's Chief of Staff. ahead. go Please

Heather DiVecchia

quarter and summarizing during Howard, website on the www.gamidacell.com. everyone. to across issued which the Welcome and Earlier company, of Thank morning, the financial this we good website results will our at call, we fourth for results which our press on available full provide today's at year review XXXX. release you, a financial morning, and our an is company progress update and

call are Officer; and Officer Officer Julian our our Executive on Ronit Simantov, Medical Commercial Chief Shai Operating me Chief Officer; Financial Officer. and with Here Officer; today Chief and Chief Chief Michele Adams, Lankry, our Scientific Chief Korfin,

of potentially including for expectations commercialization in to projected Omidubicel and of call, of, data including and the and our candidates, to timing to we regarding the and curative respect progress make for runway. potential cash initiation filings, regulatory this product Omidubicel, activities from of FDA, about our commercial used may trials be plans, the or and life-saving our anticipated cash clinical reported statements the BLA the of During and forward-looking submission future the operating our expectations efforts, planning therapeutic,

and such building and thereof, and safe of candidates that for are the human impact use endeavor a whether and materially those progress annual only Our factors, views on information, -- effective process candidates, business trials clinical, a considerations operations, number of we pandemic that and future filings most inherent statements product with we the of the time. scientific, time update you Risk today including commercializing XX-F represent our COVID-XX clinical that in not to as a actual that of our may recent and expansion from our events section and cost SEC caution we make future, the results and of new Form regulatory technical and project of forward-looking These developments, scope, differ report as make filings the we other from we therapeutics, our described developing on as result today, important otherwise. may of the the what those other in product due or Factors to fewer them impact of and around as in well as

like to I'd to the Now, turn over call Julian.

Julian Adams

you, Heather, this Thank thanks morning. and us joining everyone to for

the impacting take in moment Before globally world I over major weeks. begin, the the want acknowledge I past to that Ukraine, a to few are events the

in the occurring we with have global advancements and cell are therapy. field be our our any While Gamida At of the thoughts all Cell, we are as to affected. in don't incredibly operations expect to proud minimal those citizens, significant of part Ukraine or operations, Russia impact the

suffering from As to stage of as and and was XXXX -- benefit an disorders. toward hematologic clinical it cell Omidubicel important us two potential grow patients which progress patients need. GDA-XXX. and to for significant blood progressed continues our progress we programs, hold in Both cures therapy serious year malignancies NAM-enabled for

with evidence to resource our in today's NAM-enabled data reduction hematologic expertise our treat lead cell efficacy, breakthrough economic first Additionally, the we the of XXXX, a designation in to which potentially impact and potential NK also Throughout has tumors. for which demonstrating positive several addition data of start contribute stem NK therapy the us to presentations platforms we be FDA-approved Omidubicel, utilization. healthcare the potential Omidubicel's therapy for health and by further our cell call announced to and commenting constructs, expanded cell program, transplant. Omidubicel, modified with various allowing leverage genetically will I solid cells NAM-enabled the malignancies on

in on we The of call, later the BLA very robust generated potential this have healthcare data last that the important and in As hospitals, reduction for exciting and milestone most rolling Omidubicel of Ronit namely payers. utilization initiation month, for in the this for describe is our us to recent support patients, resource will led Omidubicel.

our study. also Israel following meeting receipt the commercial from the of the submission FDA the In confirmed FDA. the This non-clinical analytical our between FDA. the comparability the were in With clinical at submitted Omidubicel module -- produced Phase focused the CMC module month, manufacturing Type positive receipt for manufacturing the clinical owned correspondence, sites facility that we batches wholly of B to our recent to correspondence this three

the We track full quarter. BLA end complete the of by the submission and remaining -- second the modules submit to are on and complete the

inflection and We to point as the this forward to FDA are soon have with working patients to bring as look Omidubicel reached possible. to thrilled

their an on properties, pipeline, leverages GDA-XXX. cells proprietary GDA-XXX cytotoxicity functionality, or expand cell tumor we is also Beyond ADCC. are to Omidubicel, our our NAM-enabled technology enhance antibody-dependent developing natural killer NK killing by direct led which platform cellular to NAM

diffuse large XXXX, We one which responses where an lymphoma. investigator to are and patients study, and with phase in cryopreserved we complete B-cell GDA-XXX both trial large diffuse formulation lymphoma follicular in B-cell with encouraged follicular lymphoma the highly the potential GDA-XXX, application sponsored produced In in seen remarkable have truly of phase FDA September two a one we for of durable submitted results and by IND high lymphoma. has a a very

FDA to clinical being in donor about of Following patients and XX, placed qualification. on assay procedures hold this eligibility we since November submission, the dose were had questions prior

and an initiate their phase one/two we in plan this comments actively to to enable IND are study. year, We working dosing with FDA This the acceptance study initiation. address to

Last combined of for us a product tumors. modified solid utilize cell therapy we and CRISPR enabled cancers a persistence targeting mediated lines. genetically the and has tumors. NK NAM NK curative announced with against to NAM-enabled cell GDA-XXX, Furthermore, against increase promising solid CDXX as CAR that knockout and confidence broad construct candidates hematologic a Robust for preclinical gives evidence both Moving new product Dana-Farber year, our a potency Cancer excited CAR malignancies to establish programs. NK were preclinical that myeloma to candidates newest candidates, hematologic product we strategies CRISPR the pipeline collaboration NK with multiple demonstrated these that a hold research results therapies potentially promise cell CDXX Institute and

execute multiple vitro to select of the enabling studies. of We plan study NK at proof in researchers the end are excited a Throughout we leverage activity the concept IND for of modified cell expertise studies these XXXX, GDA-XXX myeloma. and Dana-Farber for candidate to killing of by to XXXX, genetically preclinical NK targets, therapeutic in pipeline

dedication we we therapies are brought of is about patients, advancing am in our where encouraged future course, needs the we us unmet holds patients. in be for Gamida focused With achieved wouldn't what XXXX, to focus employees, which without Cell this the to possible proud today. of on progress and I 'XX. And for grateful address determination has for their on help are and continued whose

like call turning take recent Ronit, on congratulate I her to moment would over Before a to the to her promotion.

-- work of and role. at officer, expanded Now, your role we assuming scientific look your you medical toward thus the for thank Ronit? only your forward chief far, officer but also continued Gamida to medical vision contributions all the not with chief

Ronit Simantov

cells. demonstrating Omidubicel. for Omidubicel. through translational and good free in healthcare our the of scientific broad alternatives opportunity clinical and weeks for and Omidubicel phenotype platform, XXXX, were the hematologic experience, patients and cells results we were of for treated modulation clinical together, to generates on range clinical everyone. cellular our to data Thank the leading highly with poetic had translational need recovery, translational subsets, in shorter In note, transplanted malignancies, which demonstrated T functional rapid dendritic showed support the natural and in Thanks, of cells had Julian, or value pathways with presentations infections we October you three long-term nicotinamide or decreased and we B on transplant somatic pre-clinical a critical for present system. data functional clinical to that unique transplant. potent Tying NAM allogeneic data, few call. In stem and no results XXXX, in with our trial analyzes Of that and data, robust joining our XXXX, patients metabolic outcomes, randomized a us with patient clinical reconstitution provided morning, following significantly duration trial. mechanistic of hospitalization patients phase available. published and of in days of The of cell the global killer The In

over and totality and time to the experience procedures, We patients life. back Omidubicel, blood XX years of follow-up Omidubicel Looking we Salt with at immune therapy healthcare on [Inaudible] month's At Lake long-term studies Omidubicel healthcare quality in resource including cost intensive treated had patients. in patient related utilization, could health planned and new as transfusions, transplantation from and units. decrease on outpatient data eight cellular have clinical sustainable that of show reduced the of to care abstracts then demonstrating the we went outcomes focused accepted and data competence presented meetings in City, to report next system, with our

cell the Omidubicel need experience, as Taken package of we add the in we patients have scientific are a transplant. to make value clinical activity, together, we and of to efforts mechanism have of and continued body action, a in to assembled, confident stem hematopoietic life-saving Omidubicel patient potential to clinical our the of Moreover, therapy. evidence and supporting available

we considerable and phase of in exhaustion sponsored of regulating median are rate lymphoma. cells, response showed overall platform. survival in We highly shown and patients cryopreserved of similar We while were XX%, line duration in by XX% also overall sponsored with that reported developed expanding multi-center typically natural NK follicular a in B-cell cell data a of of supported year at vivo stress, out formulation induced to NK lymphoma and company ASH, clinical the with in study the our cells down previously GDA-XXX. reported pathways plan vitro in progress one toxicities cytotoxic data an University activated those We've showing assays. NAM in are characterizing mediates memory this study rejuvenated and in large We At that with the cellular GDA-XXX. and processes, be lymphoma, presented cytokine presented now non-Hodgkin in including XX made to investigator patients initiate Minnesota. year culture. two the responses were diffuse complete findings to follow-up killer for GDA-XXX a cells by NK NAM-based and phenotype cellular properties These XX response months. characterized with of like differentiation, XX preclinical data in a set

tremendously enabling IND NAM of concept each which GDA-XXX talk GDA-XXX, over Overall, we turn validate our Michele, and productive genetically was is modified for year look development NK will as expanded reported research. with we advance and research studies In platform continuing toward proof the clinical GDA-XXX, We product and to more develop to our potential addition, proceeding studies. we Michele? who candidates. call of will of that upon have toward preclinical in therapeutic now XXXX to our Omidubicel. a about launch readiness the cells, I

Michele Korfin

Thank off morning, our already, you, last Ronit, good initiated year for This rolling BLA has we strong started everyone. month submission and as Omidubicel.

preparation. on our commercial in toward study extremely excellent of our Omidubicel. the continue we phase with Omidubicel. facility Omidubicel for milestone owned We the advancing parallel for of three FDA Gamida potential are from cell insights, Based has potentially as focus Israel. in planned market -- was of reach the cell hematologic malignancies. patients allogeneic the FDA-approved transplant is we The additionally submission, acknowledgment advancing used The commercial strategic with be our as assessment Omidubicel Omidubicel, commercial to rolling continue we for compared analytical encouraging. the to continued expand on commercialization progress advanced potential including BLA opportunity for work In make the stem the alternatives of partnerships facility important to therapy our facility product to our and comparability to manufacturing hematology an first Gamida assessing

finding observe to deemed age In X,XXX eligible year regards appropriate transplant malignancies transplant U.S. stem chance allergenic malignancies Unfortunately, stem cell for each year. cannot who malignancies a very Unfortunately, we match stem the access but allogeneic XX, have are above aged we approximately patients transplant, find are transplants. of hematologic are patients are procedure of and family stem who the that not potential in is for eligible database. U.S., cell each with cure. undergo to Few a their access public with in patients non-caucasian member are do for also there an XX though, the have likelihood a hematologic best to hematologic the the low and allergenic an there an deemed with a allergenic are For who donor, cell X,XXX disparity cell an donor. racial in up approximately

XX% patients example, a African-American who finding have only may are match. chance For about a of

need is For stem often cell only a transplant, in their cure. a chance patients of this for

top meetings centers centers advance one suitable working that improve at and the XXX of for XX matching to cell cell to transplants. patients. medical approximately Based that allogeneic continues are transplant clinical the and indicates those are compared of to outcomes one diligently a less XX In for transplants, Omidubicel sources, our and Omidubicel data conferences. expand We about perform potential the stem there to engage the donor and on cannot allogeneic medical on U.S., and feedback criteria, donor. find expand through those transplanters to team centers other has with stringent stem transplant patients to encouraging conduct XX% who access patients access

from assess to the also the upon market X,XXX X,XXX equates to We reaching continue This market share XX% of We treat to to approximately population. potential to XX% market the Based extensive in market U.S. peak per approximately see year Omidubicel on transplanters insights addressable patients share. for research.

we date. turn of to economic over be the market to engaging stem of recognize for results. are data to to Our access commercial we also potential feedback transplant. payers, allogeneic encouraged regional FDA-approved the data physicians Omidubicel will summary, the encouraging. in clinical published and In payers. is with Shai, by first proposition, strength by now And excited be review health the meetings the Omidubicel including the and to the continues therapy from are cell we feedback team value cell call our and the I also financial overall the Payers and actively clinical and data very have national

Shai Lankry

morning, Thank the full Michele, year you, good XXXX. and results I for will summarize of Today, everyone. our financial

were our approximately development last XXXX, expenses increase and capabilities increase same XX, million readiness headcount was in of and organization. commercial the broadening million December the and compared $X.X in of Omidubicel were The million, and million, advancements increase position in $XXX.X to $X.X As due activities mainly programs, well due for million a of $XX.X $XX NK period compared to to was as our increase million $XX.X Commercial million $XX our increase Research the XXXX. XXst in $X.X in to to was increase XXXX. commercial of total talent. $X.X a at within as manufacturing expenses an scientific December primarily for in XXXX in The our expenses million, cash year. year compared million $X.X commercial readiness million

of The was expenses due net $X.X in services Finance capitalization million loss $X.X million expenses, General and increase a alternative million to in in reducing $X.X compared XXXX, our XXXX, compared cash were in other and commercialization increase million our anticipate million million loss expenses. U.S. due $XX.X XXXX. was The in $X.X $XX.X as $X.X expenses convertible XXXX. we forward, a to $XX for Omidubicel compared to interest management. and in including related the a of professional in are notes headcount XXXX. increase by was to $XX.X near-term interest to increase readiness offset million assessing global primarily commercial a mainly net potential in or in million and Net a increase partnership. million Going expenses million XXXX $X.X expenses we rose administrative from non-cash in income $X.X income million

that one way to current now may million. ongoing mid-XXXX. to business cash activity range on Julian. to for be over I or cash and cash from use total funding development guidance recurring continue year received million our into excludes that back this plan activities is support the anticipate operational the turn based may activities $XX call be ongoing will any $XX additional undertaken. will position operating to expect our We operating We This

Julian Adams

Thank you, Shai.

are look ahead deliver year, for tumors, to what developing cancers, solid our one/two submission As believe cell year. this blood we XXXX. potentially curative other in well-positioned our our mission we Gamida's quarter patients to BLA toward on and cell set sponsored second serious the out and into of I for of this And blood multi-center disorders. with planned in GDA-XXX we for initiation Omidubicel, full therapies the We lymphoma. expected have phase look accomplish study of non-Hodgkin

unique throughout updates NAM-enabled across to We continue forward a I opportunity of providing year. therapies. to range our are leveraging excited the cell the And platform look broad for

questions. open will for call Operator? we Now, the

Operator

from from first Miller Our comment question comes Instructions] or line Jonathan the ISI. [Operator Evercore of

Your line open. is

Jonathan Miller

Thanks questions. my guys. taking for Hey,

clarity. [ph]? IND clinical maybe color reinstated, get bit you last guidance maybe runway thoughts similar maybe is language in what see commercial like here happy additional wanted guidance but on to to to included And had in guidance? the update. recent I GDA-XXX. to secondly, just how the for First, How are then current and any interactions that and work seems much get It your that And some if on with I'm feels current -- the prep much a ability and is GDA-XXX wondered just little runway agency, included your the

Julian Adams

addressing first So of by question. part your let begin the me

provided absolute the are of we amendment resolved be Most had communication haven't IND, clarity we'll those issues resubmit we the accepted. the when and to The with to We ready is and announcing direct the are any issues on FDA. getting FDA needed resolve. to IND what

Michele me guidance, runway talk and GDA-XXX. support launch cash of readiness turn and over Shai use it to Michele? to about let of Regarding forge

Michele Korfin

Jonathan. morning, good and Julian, you, Thank

turn I'll then Shai to additional and financials. start I'll Jonathan, the So for

complete to commercial that key the we OpEx. for discussed Shai regards lot a for in milestones to increase so preparation of guidance, were led XXXX, that the to runway able So for

So insights quantitative the some payers. as from of assessments those and from included, such transplanters market feedback

very Gamida of In although Assist, identity milestone organization. starting It monitoring the addition Cell and of of identity chain of and of chain for Gamida sits was Cell very, plays in XXXX, in the critical readiness the role custody. the commercial a important us within chain

Although Omidubicel XXXX. and chain was completed of work including we processes, the in individualized Gamida building hence need of Assist, still the Cell chain has That custody. an to therapy identity less for infrastructure stringent IT requirement, developing key the is it team, establishing demonstrate all and

in strategic launch. So what do to of commercial 'XX. allowed the for to or XXXX fact strategic the alternatives we some much potential in It the us assessing us decrease alternatives so to our that done allowed are in that of had been as preparation spend because regards

the let us turn you to financial any So me we'll details. give follow-up Jonathan, to And questions. see then if actual Shai have

Shai Lankry

Michele. you, Thank

your I the answer So, question, Jonathan, for two. would into divide

in [indiscernible] guidance. process did of commercial. Michele can XXXX meet internal cash expense for did prioritization the few less continue way an And months. be As some our spending, as to the order next will which of the And for reduce addition, critical previous in activity advanced. in robust comments, you to all are that the the tell in in critical I the one we we -- We mentioned

that of -- As prioritization, can assure I particular, GDA-XXX. part GDA-XXX the for didn't the we and of the as -- did we advance that continue of R&D as to GDA-XXX, any we in reduce part the you

patient and of the advance trials program, first year initiation later to in. this including this continue potential We

Jonathan Miller

Thanks so guys. much,

Julian Adams

Jon. you, Thank

Operator

you. Thank

Piper question Sandler. from of or Tenthoff Ted the Our comment next from comes line

open. is line Your

Ted Tenthoff

and very everybody. much, morning, Great. Thank good you

like you more this marketing. it greatest the how give if I would considering. to overseas it be you're you're us best of a U.S.? maybe sense the assessing want deal to for respect retained terms how keep of deal? on kinds can Thanks. you what just this? where more in global Could we value me, bit this But be that be market do Could take a with bit a the what options this therapy a dig and Give a you little So seems to is considerations little in To yourself. to

Julian Adams

you thank Ted, morning. question So, your good and for

that's patients to in Omidubicel. our was by as alternatives our possible, for desire driven access see Omidubicel, As to and script, as gain the many mentioned we're strategic assessing

discussing potentially portfolio, So and hematology-oncology to as well with interest a as partners franchise in that unique possible. we infrastructure up as patients pairs significant Omidubicel are with deals many potential regional regional and their deals, able may the to to already deals, as U.S. has deliver be that on have

because be of know the will you Our always and product. facilities we involvement manufacturer very kind the in manufacturing are to critical as cell is any intimate, therapies, supporting commercial

yet. conversations BLA and we're with made up for So haven't interested we open will filed that any And certainly avenues accepted, parties. starting is the once fully and choices

Ted Tenthoff

helpful, And Yes. truly. I appreciate additional Very that color.

Julian Adams

pleasure. My

Operator

you. Thank

from Our line question the JMP of Jason comes next Butler Securities. from or comment

Your open. line is

Jason Butler

thanks taking the question. for Hi,

including access the talk data Omidubicel. on another from Just you. expanded Can extended extension -- label you additional this plans about Thank just to program? open for presentations year,

Julian Adams

we So where mentioned abstract thank could Omidubicel. perhaps dataset your Jason, have TCT, but eight for the Ronit during we other prepared for might the you, highlight present question. that you Ronit, remarks, venues maybe maturing

Ronit Simantov

Jason, and Absolutely, thank question. your for you,

I mentioned, preclinical as well well, and as health of be and focusing information, of and value reconstitution reported So on care. follow outcomes, quality patient on cost life, related as data the some some immune additional long-term up as information data a TCT, we'll

recruit to access what have expanded either time present program patients. a, at the end decision the we program, continuing is transplant meeting. that think, cohort amount expanded by that there of year the are we will the when worth next definitive be But would certainly patients to about at not of access critical growing maybe the terms the meeting a for In appropriate a presenting, do or year that's I of hematological of information made

Jason Butler

you. Thank Great.

Operator

you. Thank

Needham & from comes next Gil line Our Company. or question the of comment from Blum

is open. line Your

Gil Blum

our and taking Good morning, thanks for questions. everyone,

so your here feedback on what their that an an FDA-approved date? interest one's regarding far. opinion heard FDA-approved with focus something the they've been have feedback physicians, From doing this Michele. what and you been versus that for transplant you've in are The discussions is whether So being getting to they

Michele Korfin

We speaking for lot physicians to we've following. encouraging Thank what work is done which falls of morning. into is -- Gil, -- therapy FDA-approved and good them Omidubicel, category an what of the you, a about the and

take on the from all responsibility center. chain the way of Omidubicel the So, the the first around the of and off, Omidubicel of custody from the patient return of through chain to selection the identity time therapy will

and important that comes something an being that's So FDA-approved that's with an responsibility, therapy.

The other is aspect Omidubicel around the itself.

the NAM to enhance expand So the technology not allows cells. only us but

And I of the the defined sources associated affecting of adequate with data, that other to a donor the clinical cells. Omidubicel we Omidubicel have see a co-morbidities with feedback some their that around ability? transplant say Omidubicel the of challenges that donor ERS is be consistently that sort using they as have for see threshold patients is U.S. will hear regulated is key some falling number opportunity into two fact viewed potentially Does when release criteria, the from positive. they categories. the be an therapy we donor that an will So could FDA potentially with

of improve first the The of to those outcomes we we using. to eligible patients XX% one perpection the for clinical then approximately second our a compared find very transplant demonstrated see study. we criteria, study fact for opportunity our important they very Omidubicel, stringent that in less And that the were who a have can't -- as non-caucasian had but a match, physician's matching given in donor clinical currently patients from the critical is perspective, ability they're deemed were that sources

we So consistently those to really do resonate when physicians. two speak opportunities key

Julian Adams

with have if specifications are no us behavioral If an Michele. may them will question to clearly experience I in a that encouraging if patients long There's for label and engage a to product Omidubicel. good physicians that gives having Omidubicel go this an suitable and prescribe is FDA quality find economics, physicians that to and will. to add, way and the exercise opportunity And you a educate, with continue over time, assured

transplant. for we the game first ever stem FDA -- So is a study for think hematopoietic field of three label the cell changer an sponsored phase randomized that significant

Gil Blum

Michele, thank taking you, right. Thank All you, Julian, question. for and our

Michele Korfin

Gil. you, Thank

Julian Adams

Thank Gil. you,

Operator

[Operator next Global. Instructions] Cross Alliance the or line Our Matthew comes of comment question from from

is line Your open.

Matthew Cross

Hi, on wanted as asset thanks a NK what's these -- I previously and finalizing with you're tested that couple cryopreserved a to I ask requirements hoping these broad clinical on in non-cryopreserved just good Both the supply for issues recap of both get was me. cold for regarding supply GDA-XXX. for taking you'd the required I XXX, side. terms and given product the particular, of for and that a morning, for cryopreservation One, Omidubicel at IND a for continuing status know product. questions chain to chain the Since level. FDA in cell

Julian Adams

of So, let me and take months product The cryopreservation. with that stability worked maintain stability, have the We perfect on. through XXXX optimize that team liquid to has very many and diligently now nitrogen.

to -- enable So with one/two study, phase to the a with goal single and GDA-XXX. a to of able patients product be this recruit is have shelf an the multi-center off treatment

activities to, the to FDA just attended those of and all to finalizing So clinical the and been begin resubmit study XXXX. to IND we're have the amendment the in

Matthew Cross

Or overly, Are one frontrunner a this literally. of the will looking year? all for and you during at year the for NK confirm progress, IND to [ph] you're the making of program. appreciate whether one year candidate modified wanted tabling these Thanks. enabling genetically Julian, select that this these a maybe taking that stated statement had just confirmation kind Thanks, IND a cell just and bit? of okay. of then studies it, out you programs there. to Got looking become I'm But to And advancing rest four

Julian Adams

very Matt, So, you question. thank your important for

at further comments us have So patient pretreated. we lines, collaboration candidates look about fresh and right who patients GDA-XXX as all now, Dana-Farber with driven, to are allowed three as to that myeloma data who have cell expand heavily been It's isolates, are my progressing. well our multiple

studies, make to going IND candidate on progress most data So select for candidates. it'll the the candidate all Again, forward. the other data the subsequently be continue enabling three, one we'll select and idea is compelling but then and with progress driven, all

Matthew Cross

Great.

clarification I the well. there the answers. for all thanks appreciate Okay, as

Operator

-- Julian for queue back questions at closing the this Thank remarks. you. turn in over conference the additional to in to I'm additional I'd any time. like Adams showing the queue no

Julian Adams

and operator, joining today's good you, to for call. next Thank We us and thank with a you engaging have look forward quarter. you on everyone and everyone, see you day

Operator

concludes gentlemen, and program. in you conference. thank today's participating This Ladies the for

You a wonderful may have disconnect. Everyone, day. now

Gamida Cell (GMDAQ) 15 Mar 222021 Q4 Earnings call transcript